MAPS opposes DEA proposal to place five tryptamines in Schedule I
Statement on DEA attempt to reschedule five tryptamines
MAPS has stated its opposition to a DEA proposal to place five little-known psychedelic compounds, 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET and DiPT, in Schedule I of the Controlled Substances Act. The organisation says this is the agency's second attempt at the same scheduling action, after an earlier version was withdrawn in 2022 following pushback from researchers and legal advocates.
Key facts
- Kind of item
- Regulator decisions
- Compounds
- DMT and ayahuasca, Novel compounds
- Organisation
- MAPS
- Regulator
- DEA (United States)
- Jurisdiction
- United States
- Source
- MAPS (maps.org)
- Published
- Original
- Read it at maps.org
How this summary was made
The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method
Source: MAPS · maps.org
Connected to
- Kind of item
- Regulator decisions
- Compounds
- DMT and ayahuascaNovel compounds
- Organisation
- MAPS
- Regulator
- DEA (United States)
- Jurisdiction
- United States